A Single-center, Open-label, Two-treatment, One-sequence, Cross-over Study to Investigate the Effect of Clopidogrel on the Pharmacokinetics of Selexipag and Its Active Metabolite, ACT-333679, in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 05 Jun 2018
At a glance
- Drugs Selexipag (Primary) ; Clopidogrel
- Indications Arteriosclerosis obliterans; Pulmonary arterial hypertension; Pulmonary hypertension; Raynaud's disease; Spinal stenosis
- Focus Pharmacokinetics
- Sponsors Actelion Pharmaceuticals
- 31 May 2018 Status changed from active, no longer recruiting to completed.
- 07 May 2018 Planned End Date changed from 1 Jun 2018 to 18 May 2018.
- 07 May 2018 Planned primary completion date changed from 1 Jun 2018 to 18 May 2018.